Meanwhile, Chinese companies are rapidly advancing through fast following, innovation and licensing, with key developments including Innovents mazdutide, Innogens supaglutide, Hengruis oral candidate HRS-7535, United Laboratories licensing of its first-in-class triple-G (GLP-1, gastric inhibitory polypeptide (GIP) and glucagon) a gonist to Novo Nordisk and Ascletis positive Phase 1 results for its oral + injection candidate, ASC30
Tu Q, Zhang J, Dong LQ, Saunders E, Luo E, Tang J, et al
BPC-157 has never been tested in actual ADHD models or evaluated for attention, hyperactivity, or impulsivity in relevant paradigms
He is experienced in military medicine, an FAA medical examiner, human performance expert, and fighter pilot
Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy